PriceSensitive

Fiji Kava (ASX:FIJ) appoints Dr Anthony Noble as CEO

Consumer Discretionary
ASX:FIJ
04 May 2021 12:30 (AEST)

Medicinal kava company Fiji Kava (FIJ) has appointed Dr Anthony Noble as CEO, effective May 31, 2021.

Dr Anthony will be taking over from interim CEO Nicholas Simms who will transition back to his role of Non-Executive Director.

“It’s an absolute pleasure to welcome Anthony to Fiji Kava, further strengthening our experience and capabilities at an Executive and Board level,” Nicholas said.

“We believe he is the ideal candidate to build on our continued growth both domestically and internationally and capitalise on the strong foundations for growth,” he added.

Currently, Dr Anthony is the CEO and Managing Director of Australian Biotherapeutics, roles in which he has been in since 2019.

At this company he contracted and commissioned a best-in-class bioreactor facility in Queensland, which came off the back of a large distribution contract in the U.S.

Dr Anthony has also worked at SFI Group where he was Managing Director of SFY Research and Global Head of Innovation.

Furthermore, he was also SFI Group’s Head of North Asia, Business to Business and General Manager of the company’s Chinese joint venture.

Prior to joining SFI Group, Dr Anthony worked at Cryosite and in the U.K. at the Human Tissue Authority.

“Fiji Kava has an incredibly unique story and position in the market, along with a strong board and management team,” Dr Anthony commented.

“I’m delighted to be joining at this critical juncture for the company and to continue to further its strategic ambitions in Australia and abroad,” he added.

Shares in Fiji Kava are up 7.69 per cent on the market and are trading at 14 cents at 11:09 am AEST.

Related News